The acquisition by royalty management company Zymeworks follows a "strategic review" triggered by the failure of a drug for a type of low blood pressure.
An article from
Dive Brief
The acquisition by royalty management company Zymeworks follows a “strategic review” triggered by the failure of a drug for a type of low blood pressure.
Published June 29, 2026
Zymeworks announced a deal to acquire Theravance Biopharma on June 29, 2026.
Zymeworks to acquire troubled biotech Theravance in $929M deal
Zymeworks acquires struggling Theravance for $929M
Zymeworks Targets Long-Term Cash Generation Through Theravance Acquisition - Theravance Biopharma (NASDAQ
THERAVANCE BIOPHARMA ENTERS INTO DEFINITIVE AGREEMENT TO BE ACQUIRED BY ZYMEWORKS FOR $17.00 PER SHARE IN CASH PLUS A CONTINGENT VALUE RIGHT
Merck KGaA Swoops In With $11.3 Billion Medtech Buyout
Valerio Therapeutics Announces Binding Offer for the Proposed Acquisition of Etherna Immunotherapies, Creating a Global Leader in Targeted RNA Medicines
Verastem's KRAS G12D vision; ADC Therapeutics reorganizes, lays off 17% of staff
Zymeworks to acquire Theravance Biopharma for $929M, gaining rights to COPD drug Yupelri's US profit share and ex-US royalties…
Four months after Theravance Biopharma shut down its R&D unit, laid | Four months after Theravance Biopharma shut down its R&D…
Zymeworks will acquire Theravance Biopharma for $929 million, adding YUPELRI cash flows and expanding its portfolio.
THERAVANCE BIOPHARMA ENTERS INTO DEFINITIVE AGREEMENT TO BE ACQUIRED BY ZYMEWORKS FOR $17.00 PER SHARE IN CASH PLUS A CONTINGENT…
The deal expands its portfolio of life sciences tools.
The data showed that del-brax, an “antisense oligonucleotide conjugate” being tested against a muscle-wasting disease, met its…
